Last reviewed · How we verify
PF-07275315 dose 1 (pf-07275315-dose-1)
At a glance
| Generic name | pf-07275315-dose-1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07275315 dose 1 CI brief — competitive landscape report
- PF-07275315 dose 1 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI